Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell 
Lung Cancer Patients with Acquired EGFR T790M Mutation

Background and objective Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) capable of overcoming non-small cell lung cancer (NSCLC) with EGFR T790M mutation. Although the addition of bevacizumab to 1st generation EGFR-TKIs confers a significant...

Full description

Bibliographic Details

Published in:	Chinese Journal of Lung Cancer
Main Authors:	Yanfei GU, Xiaoru TIAN, Ruotian WANG, Xiaoxue LI, Kun QIAN, Yuanbo LI, Jingying NONG
Format:	Article
Language:	Chinese
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2022-12-01
Subjects:	lung neoplasms epidermal growth factor receptor vascular endothelial growth factor osimertinib bevacizumab
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.56